FDA 483 OBSERVATION · #74 OF 1,923 MOST-CITED
Component - qualify supplier
FDA cited this observation 344 times across 283 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A dietary-supplement manufacturer relied on a supplier’s certificate of analysis for a component without first establishing the reliability of that supplier’s analyses through appropriate qualification, so the certificate was trusted without a basis.
Why FDA writes it — A certificate of analysis is only as good as the supplier behind it. Under dietary-supplement CGMP you may rely on a COA for certain attributes, but only after qualifying the supplier — otherwise you are accepting unverified data as the basis for using the component.
- Conduct your own identity test on each incoming dietary-ingredient component (this cannot be replaced by a COA).
- For other component specifications, you may rely on a supplier’s COA only after first qualifying the supplier by confirming the reliability of its analyses (e.g., through your own periodic testing), and reconfirming periodically.
- Document the qualification and the basis for relying on each COA.
- Reject components from unqualified suppliers or when COA reliability is not established.
- Accepting supplier COAs without ever qualifying the supplier’s analyses.
- No periodic reconfirmation, so an initially qualified supplier is trusted indefinitely.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.8× the rate of the average FDA-cited firm (29.7% vs 7.8%), across 283 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
You did not qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations.
You did not qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations.
You did not qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations.
You did not qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations.
You did not qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations.
You did not qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →